Clinical Ink Ranks No. 57 on Inc. 5000 List of America''s Fastest Growing Companies
Rapid Adoption of Clinical Ink's Paperless Clinical Trials Platform Drives Three-Year Sales Growth of 4,613%; Fastest Growing Company in Pennsylvania and No. 6 Among Healthcare Companies
(firmenpresse) - PHILADELPHIA, PA and WINSTON-SALEM, NC -- (Marketwired) -- 08/13/15 -- , the pioneering provider of eSource solutions for clinical trials, today announced that Inc. magazine ranked the company No. 57 on its 34th annual Inc. 5000 list, an exclusive ranking of the nation''s fastest-growing private companies. Clinical Ink experienced cumulative three-year sales growth of 4,613% fueled by increased adoption of the company''s paperless clinical trials platform by life science companies.
"This recognition is a testament to the progress we''ve made pioneering eSource technology to deliver truly paperless clinical trials that have helped life science companies achieve dramatic improvements to the complex clinical trial process," said Ed Seguine, CEO, Clinical Ink. "More important than our past performance, our 2015 growth has continued to accelerate as more research sites and life science companies gain experience with our novel platform. Our solutions address the single biggest problems of clinical research -- data capture during the patient visit, remote monitoring of research site documents, immediate data availability, and streamlining workflows for research sites."
"Our goal has always been to create a paperless clinical trials platform that accommodates the needs of research sites first and foremost," said Doug Pierce, President and Co-Founder, Clinical Ink. "I''m gratified that our early efforts to transform the clinical trials process have been successful and that we''ve earned our place among the fastest growing companies in America."
Clinical Ink''s SureSource platform captures clinical trial documents and data electronically via tablets used during the patient visit. Capturing data during the visits eliminates the need to perform the time-consuming and costly process of source data verification and permits real-time, remote access to source documents and data via the SureSource web portal. Both the U.S. Food and Drug Administration and the European Medicines Agency endorse and encourage eSource data capture and remote monitoring to improve the safety and efficiency of clinical trials.
Clinical Ink ranks among the top tier of the Inc. 5000 as one of 500 companies featured in the September issue of Inc. magazine. The 2015 companies are the most competitive crop in the list''s history with average three-year growth of 490%. For additional information about the Inc. 500, please view the .
Founded in 2007, Clinical Ink is dedicated to transforming clinical development -- from Start to Submit™ -- by delivering completely paperless clinical trial solutions for sites and patients. Clinical Ink''s SureSource platform is purpose-built to capture eSource data and documents electronically at the site, while the CentrosHealth patient engagement platform provides patients with a variety of configurable apps to keep them informed, involved and compliant throughout the duration of a clinical trial. Clinical Ink maintains offices in Winston-Salem, NC; Philadelphia, PA; Cary, NC and Cambridge, MA. Additional information is available online at or toll free 1-800-300-5033.
Image Available:
Alicia Maguire
Clinical Ink
336.464.0696
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.08.2015 - 08:56 Uhr
Sprache: Deutsch
News-ID 1378945
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
PHILADELPHIA, PA and WINSTON-SALEM, NC
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clinical Ink Ranks No. 57 on Inc. 5000 List of America''s Fastest Growing Companies
"
steht unter der journalistisch-redaktionellen Verantwortung von
Clinical Ink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
